Post marketing surveillance of new drugs. Patient safety in the hands of GPs.
Is the post market surveillance--the monitoring for safety and tolerability of new drugs--reliable? Will it become compulsory? How does it compare with current detection methods? How reliable are promotional claims drawn from it? This review is a guide to the present, and the implications for the future for general practice.